{"article_id": "ROP_q1_2021.txt", "article": ["as we turn to page 5 , we got off to a better start than we expected .", "in addition , we continue to see accelerating software recurring revenue growth , growing approximately 6 % on an organic basis .", "the growth in cash flow performance in the quarter allowed us to continue our rapid deleveraging with about $ 500 million in debt pay - down during the quarter .", "turning to page 6 and covering the q1 financial highlights .", "total revenue increased 13 % to $ 1.53 billion , which was an all - time record for any roper quarter .", "organic revenue for the enterprise declined 1 % versus last year 's plus 4 % pre-pandemic comp .", "ebitda grew 20 % to $ 561 million .", "ebitda margin increased 220 basis points to 36.7 % , on really great incrementals across the portfolio .", "adjusted deps was $ 3.60 , 18 % above prior year .", "free cash flow was $ 543 million , up 54 % .", "our results were enhanced a bit by approximately $ 40 million of accelerated payments that were the result of wins at our uk - based clinisys laboratory software business .", "aided by our outstanding cash flow performance , we reduced our debt by approximately $ 500 million in the quarter .", "turning to page 7 , an update on our deleveraging .", "in the first quarter , we reduced our debt by approximately $ 500 million .", "over the first three months of the year , our ebitda growth , combined with debt reduction , enabled us to lower our net debt to ebitda ratio from 4.7 to 4.2 .", "as we turn to page 9 , revenues in our application software segment were $ 578 million , up 2 % on organic basis .", "ebitda margins were an impressive 44.9 % in the quarter .", "across this segment , we saw organic recurring revenue , which is about 75 % of the revenue for this segment , increase approximately 6 % .", "clinisys has approximately 85 % market share in the uk and is now recognized as one of four critical it vendors for the entire national health service .", "revenue in our network segment were $ 440 million , flat versus last year and down 3 % on an organic basis .", "ebitda margins were 40.9 % in the quarter .", "our software businesses in this segment , about 65 % of the revenues were up 4 % on an organic basis .", "this revenue was broad based among our software businesses and driven by organic recurring revenue growth of approximately 6 % .", "our non -software businesses in this segment were down 13 % for the quarter ; a touch better than we anticipated .", "as we turn to page 11 , revenues in our mas segment were $ 381 million , up 2 % on an organic basis .", "ebitda margins were 34.8 % in the quarter .", "as we turn to page 12 , revenues in our process technology segment were $ 131 million , down 10 % on an organic basis , ebitda margins hung in at 31 % in the quarter .", "now , please turn to page 14 , where i 'll highlight our increased guidance for 2021 .", "based on strong q1 performance and our increased confidence for the balance of the year , we 're raising our full - year adjusted deps to be in the range of $ 14.75 and $ 15 per share and organic growth to be in the 6 % to 7 % range .", "the 6 % to 7 % organic growth is against a 1 % organic decline in 2020 .", "our tax rate should continue to be in the 21 % to 22 % range .", "for the second quarter , we 're establishing adjusted deps guidance to be between $ 3.61 and $ 3.65 and expect second quarter organic revenue growth to be in line with the full - year organic growth rate .", "turning to page 15 and our closing summary .", "ebitda margins expanded nicely and free cash flow grew 54 % to $ 543 million , which enabled us to continue our rapid deleveraging in the quarter .", "bill has been a roper director since 1997 and has reached our mandatory board retirement age ."], "summary_gold": "sees fy adjusted earnings per share $ 14.75 to $ 15.00 .<q>sees q2 adjusted earnings per share $ 3.61 to $ 3.65 .<q>q1 adjusted earnings per share $ 3.60 .<q>q1 revenue $ 1.53 billion .", "summary_pred": "revenue in our network segment were $ 440 million , flat versus last year and down 3 % on an organic basis .<q>for the second quarter , we 're establishing adjusted deps guidance to be between $ 3.61 and $ 3.65 and expect second quarter organic revenue growth to be in line with the full - year organic growth rate .<q>the 6 % to 7 % organic growth is against a 1 % organic decline in 2020 .<q>ebitda margins expanded nicely and free cash flow grew 54 % to $ 543 million , which enabled us to continue our rapid deleveraging in the quarter .<q>bill has been a roper director since 1997 and has reached our mandatory board retirement age .<q>across this segment , we saw organic recurring revenue , which is about 75 % of the revenue for this segment , increase approximately 6 % .<q>now , please turn to page 14 , where i 'll highlight our increased guidance for 2021 .<q>turning to page 15 and our closing summary .<q>clinisys has approximately 85 % market share in the uk and is now recognized as one of four critical it vendors for the entire national health service .<q>our results were enhanced a bit by approximately $ 40 million of accelerated payments that were the result of wins at our uk - based clinisys laboratory software business .<q>ebitda margin increased 220 basis points to 36.7 % , on really great incrementals across the portfolio .<q>our non -software businesses in this segment were down 13 % for the quarter ; a touch better than we anticipated .<q>adjusted deps was $ 3.60 , 18 % above prior year .", "len_article": 35, "len_summary_gold": 4, "len_summary_pred": 13, "len_sent_scores": 35}